A Randomized, Double-blind, Controlled Combined With Open-label Phase Ia Clinical Trial to Evaluate the Safety and Immunogenicity of 24-valent Pneumococcal Conjugate Vaccine in Children Aged 2-17 Years
Latest Information Update: 17 Apr 2025
At a glance
- Drugs PCV 24 (Primary) ; Pneumococcal 13-valent CRM197 vaccine conjugate
- Indications Pneumococcal infections
- Focus Adverse reactions
- Sponsors Sinovac Biotech
Most Recent Events
- 09 Apr 2025 Planned End Date changed from 28 Mar 2025 to 14 Sep 2025.
- 09 Apr 2025 Planned primary completion date changed from 28 Feb 2025 to 20 Jul 2025.
- 24 Dec 2024 Status changed from not yet recruiting to recruiting.